{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02563340",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MSC-KTx-cAMR-150926"
      },
      "Organization": {
        "OrgFullName": "First Affiliated Hospital, Sun Yat-Sen University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Effect of BM-MSCs on Chronic AMR After Kidney Transplantation",
      "OfficialTitle": "Efficacy and Safety of Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) on Chronic Antibody-mediated Rejection (cAMR) After Kidney Transplantation: A Multi-center Perspective Study"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2015",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "November 2015"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 2017",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "November 2017",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "September 26, 2015",
      "StudyFirstSubmitQCDate": "September 28, 2015",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 30, 2015",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "September 28, 2015",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 30, 2015",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Changxi Wang",
        "ResponsiblePartyInvestigatorTitle": "Director of Organ Transplant Center",
        "ResponsiblePartyInvestigatorAffiliation": "First Affiliated Hospital, Sun Yat-Sen University"
      },
      "LeadSponsor": {
        "LeadSponsorName": "First Affiliated Hospital, Sun Yat-Sen University",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Second Affiliated Hospital of Guangzhou Medical University",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {},
    "DescriptionModule": {
      "BriefSummary": "This study is designed to investigate the efficacy and safety of allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) on chronic antibody-mediated rejection (cAMR) after kidney transplantation. Chronic AMR is diagnosed according to Banff criteria 2013 based on renal graft biopsy and donor specific antibodies (DSA) examination. cAMR patients are assigned to MSCs group or control group. Patients in control group are prescribed to current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib, depending on individual pathological and immunological features (eg. DSA type and titer) of each study subjects. Patients in MSCs group receive additional BM-MSCs therapy besides desensitization treatments as in control group. Allogeneic BM-MSCs (1*10^6/kg) are intravenously administered every two weeks for four consecutive doses. All cAMR patients are followed up for one year. Renal function, DSA level, pathological features, patient/graft survival, and severe adverse events are monitored during the follow-up period. Immunological features of patients in both groups are consecutively examined."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Kidney Transplantation"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "kidney transplantation",
          "antibody-mediated rejection",
          "mesenchymal stem cell therapy",
          "donor specific antibody",
          "acute rejection"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "60",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "MSCs group",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "cAMR patients in this group receive additional intravenous allogeneic BM-MSCs (1*10^6/kg) every two weeks for four consecutive doses, besides current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: BM-MSCs",
                "Other: Desensitization therapy (PP, IVIG, rituximab or Bortezomib)"
              ]
            }
          },
          {
            "ArmGroupLabel": "Control group",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "cAMR patients in this group receive current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Other: Desensitization therapy (PP, IVIG, rituximab or Bortezomib)"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Other",
            "InterventionName": "BM-MSCs",
            "InterventionDescription": "BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "MSCs group"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "allogeneic bone marrow-derived MSCs"
              ]
            }
          },
          {
            "InterventionType": "Other",
            "InterventionName": "Desensitization therapy (PP, IVIG, rituximab or Bortezomib)",
            "InterventionDescription": "At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Control group",
                "MSCs group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Estimated glomerular filtration rate (eGFR)",
            "PrimaryOutcomeDescription": "eGFR at month 12 after enrollment",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Patient survival rate",
            "SecondaryOutcomeDescription": "patient survival rate at month 12 after enrollment",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Graft survival rate",
            "SecondaryOutcomeDescription": "graft survival rate at month 12 after enrollment",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Donor specific antibody (DSA) level",
            "SecondaryOutcomeDescription": "Change of DSA level up to 12 months after enrollment",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Pathological manifestation",
            "SecondaryOutcomeDescription": "Change of pathological scores according to Banff 2013 criteria",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Severe adverse events",
            "SecondaryOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nkidney transplantation\ncAMR diagnosis is determined based on renal graft biopsy and DSA examination\nPatient is willing and capable of giving written informed consent for study participation and able to participate in the study for 12 months\n\nExclusion Criteria:\n\nCombined or multi-organ transplantation\nWomen who are pregnant, intend to become pregnant in the next 1 years, breastfeeding, or have a positive pregnancy test on enrollment or prior to study medication administration\nDonors or recipients are known hepatitis C antibody-positive or polymerase chain reaction (PCR) positive for hepatitis C\nDonors or recipients are known hepatitis B surface antigen-positive or PCR positive for hepatitis B\nDonors or recipients are known human immunodeficiency virus (HIV) infection\nPatients with active infection\nRecipients with a history of substance abuse (drugs or alcohol) within the past 6 months, or psychotic disorders that are not capable with adequate study follow- up\nPatients with severe cardiovascular dysfunction\nWBC<3*10^9/L or RBC <5g/dL\nHighly allergic constitution or having severe history of allergies\nPatients with active peptic ulcer disease, chronic diarrhea, or gastrointestinal problem affect absorption\nPatients with a history of cancer within the last 5 years\nPrisoner or patients compulsorily detained (involuntarily incarcerated) for treatment or either a psychiatric or physical (e.g. infectious disease) illness\nRenal graft function deteriorates due to non-immunological complication, such as surgical issues or drug nephrotoxicity",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Changxi Wang, M.D., Ph.D",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86-20-87333428",
            "CentralContactEMail": "wangchx@mail.sysu.edu.cn"
          },
          {
            "CentralContactName": "Longshan Liu, M.D., Ph.D",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86-20-87306082",
            "CentralContactEMail": "liulshan@mail.sysu.edu.cn"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Changxi Wang, M.D., Ph.D",
            "OverallOfficialAffiliation": "First Affiliated Hospital, Sun Yat-Sen University",
            "OverallOfficialRole": "Study Chair"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "The First Affiliated Hospital, Sun Yat-sen University",
            "LocationCity": "Guangzhou",
            "LocationState": "Guangdong",
            "LocationZip": "510080",
            "LocationCountry": "China"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "23263506",
            "ReferenceType": "background",
            "ReferenceCitation": "Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W, Li X, Chen Z, Ma J, Liao D, Li G, Fang J, Pan G, Xiang AP. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation. 2013 Jan 15;95(1):161-8. doi: 10.1097/TP.0b013e3182754c53. Erratum in: Transplantation. 2014 Mar 27;97(6):e37. Pan, Guanghui [added]."
          }
        ]
      },
      "SeeAlsoLinkList": {
        "SeeAlsoLink": [
          {
            "SeeAlsoLinkLabel": "Previous publication",
            "SeeAlsoLinkURL": "http://www.ncbi.nlm.nih.gov/pubmed/23263506"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000069283",
            "InterventionMeshTerm": "Rituximab"
          },
          {
            "InterventionMeshId": "D000069286",
            "InterventionMeshTerm": "Bortezomib"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000074322",
            "InterventionAncestorTerm": "Antineoplastic Agents, Immunological"
          },
          {
            "InterventionAncestorId": "D000000970",
            "InterventionAncestorTerm": "Antineoplastic Agents"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000018501",
            "InterventionAncestorTerm": "Antirheumatic Agents"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M373",
            "InterventionBrowseLeafName": "Rituximab",
            "InterventionBrowseLeafAsFound": "Test",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M3377",
            "InterventionBrowseLeafName": "Antibodies",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9336",
            "InterventionBrowseLeafName": "Immunoglobulins",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M7988",
            "InterventionBrowseLeafName": "gamma-Globulins",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M18269",
            "InterventionBrowseLeafName": "Immunoglobulins, Intravenous",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M19343",
            "InterventionBrowseLeafName": "Rho(D) Immune Globulin",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M376",
            "InterventionBrowseLeafName": "Bortezomib",
            "InterventionBrowseLeafAsFound": "Cisplatin",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M1346",
            "InterventionBrowseLeafName": "Antineoplastic Agents, Immunological",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M19757",
            "InterventionBrowseLeafName": "Antirheumatic Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}